How do you approach treatment options for patients with fibrolamellar HCC compared to "normal" HCC?  

Fibrolamellar HCC is a very rare cancer, reported to account for 1% of all primary liver cancers, and it has distinct differences compared to normal HCC. Patients with fibrolamellar are younger (20s - 30s) than patients with HCC and do not have underlying chronic liver disease, and often present wit...